Kthrough therapy designation.(43) Other 3G-TKI, nazartinib (EGF816) and ASP8273, are undergoing clinical evaluation.(44)Remedy Approach by
Kthrough therapy designation.(43) Other 3G-TKI, nazartinib (EGF816) and ASP8273, are undergoing clinical evaluation.(44)Remedy Approach by Mutation-specific Tyrosine Kinase Inhibitors SelectionWhen we talk about therapy approaches for heterogeneous EGFR populations, biases…